Adjuvanted pertussis vaccine (Dynavax Technologies/Serum Institute of India)
- Generic Name
- Adjuvanted pertussis vaccine (Dynavax Technologies/Serum Institute of India)
Whooping Cough Cases Surge Sixfold in the U.S., Reaching Highest Levels Since 2014
• U.S. whooping cough cases have increased dramatically to over 32,000 as of December 2024, approximately six times higher than the previous year and the highest level since 2014.
• The Midwest region accounts for about 25% of all reported cases, with Pennsylvania recording the highest state numbers, while Oregon has reached its highest case count since 1950.
• Public health officials attribute the surge to declining vaccination rates, with only 92% of kindergartners receiving the DTaP vaccine for the 2023-2024 school year, and the return to pre-pandemic transmission patterns.
Whooping Cough Cases Surge in the U.S., Especially Among Teens
• The U.S. is experiencing a rapid increase in whooping cough cases, with 14,569 cases reported this year, more than four times higher than last year.
• Breakthrough infections are rising among older children and adults due to less powerful pertussis vaccines used in recent decades.
• High school students in states like Pennsylvania and teens aged 15-19 in New York are significantly contributing to the surge in cases.
• The FDA is considering speeding up the development of more effective pertussis shots, with an advisory panel meeting to discuss potential booster vaccine trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath